Clinical Scorecard: Exploring the Role of Photon-Counting Detector CT Technology in Reducing Contrast Medium Use During Portal Venous Phase Thoracoabdominal Imaging

At a Glance

Key Highlights

• PCD-CT improves iodine contrast-to-noise ratio compared to conventional energy-integrating detector CT (EID-CT), potentially allowing reduced contrast medium volumes.
• Portal venous phase imaging is critical for tumor and lymph node visualization, influencing treatment response evaluation in oncologic patients.
• Contrast medium dosing protocols vary, commonly using fixed or weight-based doses; PCD-CT may enable dose reduction without compromising image quality.

Guideline-Based Recommendations

Diagnosis

• Use portal venous phase CT for optimal visualization of tumors and lymph nodes in thoracoabdominal oncologic imaging.
• Ensure sufficient iodine dose for parenchymal contrast enhancement, balancing diagnostic confidence and patient safety.

Management

• Consider reducing contrast medium volume from standard 120 mL to 100 mL in PCD-CT protocols to avoid over-enhancement while maintaining image quality.
• Use low-energy virtual monoenergetic imaging (VMI) at around 60 keV to compensate for reduced iodine attenuation when lowering contrast medium dose.

Monitoring & Follow-up

• Monitor patient BMI to tailor contrast medium dosing and exclude extremes (BMI <18 or >30 kg/m²) to maintain protocol consistency.
• Assess image quality both objectively (contrast-to-noise ratio) and subjectively (radiologist ratings) to ensure diagnostic adequacy.

Risks

• Be aware of risks associated with iodinated contrast medium, including post-contrast acute kidney injury, especially in cancer patients.
• Consider environmental and supply concerns related to iodine contrast medium use.

Patient & Prescribing Data

Oncologic patients undergoing portal venous phase thoracoabdominal CT with BMI between 18 and 30 kg/m²

Reducing contrast medium volume from 120 mL to 100 mL in PCD-CT maintains diagnostic image quality, aided by 60 keV VMI reconstructions, potentially lowering risks and costs.

Clinical Best Practices

• Use PCD-CT technology to leverage improved iodine contrast-to-noise ratio for potential contrast medium dose reduction.
• Apply low-energy VMI reconstructions (<70 keV) to enhance image quality when contrast medium volume is reduced.
• Exclude patients with BMI extremes to ensure consistent contrast medium dosing and image quality assessment.
• Maintain standardized scan protocols including injection rates, timing, and acquisition parameters for reproducibility.
• Regularly review and adjust institutional contrast medium protocols based on emerging evidence and technology capabilities.

References

• Clinical Trials Registration NCT04989192